Further investigation into the mechanisms governing the HER2-mediated regulation of HIF transcription factors is needed to fully understand the contribution of HIF-driven transcription to cancer progression in normoxia and hypoxia and may lead to new insights into how specific and non-specific HIF-targeted therapeutics can be more effectively applied clinically to the treatment of breast cancer. This evidence concerns the gene ERBB2 and breast cancer.